It investigated a novel preclinical PI3K/mTOR/PIM inhibitor (IBL-301) in vitro and in patient-derived NSCLC tumor tissues...Altered mRNA expression, including activated PIM kinase and c-Myc, was identified in Apitolisib resistant cells (H1975GR) by an IL-6/STAT3 pathway array and validated by Western blot...A miRNA array identified a dysregulated miRNA signature of PI3K/mTOR drug resistance consisting of regulators of PIM kinase and c-Myc (miR17-5p, miR19b-3p, miR20a-5p, miR15b-5p, miR203a, miR-206). Our data provides a rationale for co-targeting PIM kinase and PI3K-mTOR to improve therapeutic response in NSCLC.

over 3 years ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • PIM1 (Pim-1 Proto-Oncogene) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • MIR17 (MicroRNA 17) • MIR206 (MicroRNA 206)

MYC expression

apitolisib (GDC-0980) • IBL-301